The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic syndromes (MDSs) to AML is thought to be associated with abrogation of apoptotic control mechanisms. However, little is known about signal transduction pathways which may be involved in enhanced survival of MDS cells. In this report, we have performed immunocytochemical and flow cytometric analysis to evaluate the levels of activated Akt in bone marrow or peripheral blood mononuclear cells from patients diagnosed with MDS. We observed high levels of Ser473 phosphorylated Akt (p-Akt) staining in 90% of the cases (n ¼ 22) diagnosed as high-risk MDS, whereas mononuclear cells from normal bone marrow or low-risk MDS patients showed low or absent Ser473 p-Akt staining. Furthermore, all high-risk MDS patients also demonstrated high expression of the Class I PI3K p110d catalytic subunit and a decreased expression of PTEN. Taken together, our results suggest that Akt activation might be one of the factors contributing to the decreased apoptosis rate observed in patients with high-risk MDS.
Introduction
The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is believed to be one of the fundamental signaling pathways in the regulation of cell cycle progression, proliferation, apoptosis, and in leukemogenesis. 1, 2 Upon activation by different growth factors and cytokines, PI3K catalyzes the g-phosphate transfer of ATP to the D3 position of phosphoinositides. This lipid kinase family is divided into three classes, where class I PI3K is the most interesting one with regard to signaling in hematopoietic cells. Class I PI3K is composed of two subunits: a regulatory subunit of 50-100 kDa, activating the kinase by translocation to the plasma membrane upon receptor activation, 3 and a 110 kDa subunit with catalytic activity. 4 Cells express different catalytic p110 isoforms (p110a, p110b, and p110d), and the p110d isoform is primarily found in leukocytes. 5 Membrane localization of PI3K stimulates the generation of phosphatidylinositol (3, 4, 5) triphosphate (PtdIns(3,4,5)P 3 ), 6 which activates a number of important downstream substrates.
The serine/threonine kinase Akt is a well-characterized downstream target of PI3K. Akt activity is largely regulated at the post-translational level. Binding of PtdIns(3,4,5)P 3 to its pleckstrin homology domain results in the translocation of Akt to the plasma membrane where it is subsequently phosphorylated within its catalytic loop at Thr308, and C-terminally at Ser473. The former phosphorylation step is effected by phosphoinositide-dependent kinase 1 which is attracted to the plasma membrane by PtdIns(3,4,5)P 3 , 2,7 whereas the latter is effected by a kinase not yet conclusively identified. Phosphorylation of these two residues is required for complete Akt activation. 8 Activated Akt is known to function as an essential survival factor in vitro. 7 The antiapoptotic effects of Akt are accomplished by the phosphorylation of a number of targets, including the proapoptotic factors BAD and caspase 9, NF-kB, and forkhead (now FoxO) family members of transcription factors. 9 Phosphorylation of Bad prevents its interaction with Bcl-2 and Bcl-XL, permitting their antiapoptotic effects to occur at the mitochondrial membrane. Instead, phosphorylated BAD interacts with the cytosolic 14-3-3 proteins, resulting in inactivation of its proapoptotic function, thus promoting cell survival. 10 Phosphorylation of FoxO family members inhibits their nuclear translocation and transcription of proapoptotic genes, such as FasL. 11 A fundamental negative regulator of the PI3K pathway is the lipid phosphatase PTEN. 12 PTEN removes the 3-phosphate from PtdIns(3,4,5)P 3 to produce PtdIns(4,5)P 2. Loss of PTEN function results in accumulation of PtdIns(3,4,5)P 3 and increased signaling via the PI3K pathway, with an enhanced Akt activation as a consequence. 13 The dysregulation of PTEN is often linked to malignant transformation, and PTEN is found frequently mutated or deleted somatically in various human cancers. PTEN is therefore considered a tumor suppressor gene. 14 Ample amount of evidence demonstrates that a number of malignant diseases are associated with the constitutive activation of the PI3K/Akt signaling axis. 4, 9 Several recent findings suggests that this is also the case for hematological malignancies, such as acute myeloid leukemia (AML). [15] [16] [17] [18] Myelodysplastic syndromes (MDS) refer to a group of clonal hematological disorders, where patients succumb to a high-risk for disease transformation to AML. 19, 20 Upon evolution of MDS to AML, the progressing clonal cells present an excessive survival and decreased apoptosis. [21] [22] [23] Identification of the signaling pathways responsible for increased survival of MDS cells is of high importance as they might represent promising targets for novel forms of therapy aimed at preventing MDS evolution into AML.
In the present study, we report a constitutive activation of Ser473 p-Akt in bone marrow and peripheral blood mononuclear cells (BMMCs and PBMCs) from high-risk MDS patients. In contrast, mononuclear cells from normal bone marrow and low-risk MDS patients demonstrated low levels or absent staining for p-Akt. Furthermore, the evaluation of PI3K p110d isoform expression in MDS cells demonstrated that high Ser473 p-Akt expression was accompanied by an increased expression of the PI3K p110d isoform. We also observed that high-risk MDS patients generally had a downregulated expression of PTEN when compared to healthy controls and low-risk MDS patients.
It was recently shown that evaluation of Akt phosphorylation status 16 and PI3K p110d expression 24 in AML blasts may function as prognostic markers for AML disease progression. Our findings identify activated Akt and increased expression of PI3K p110d as potential survival factors in patients diagnosed with high-risk MDS, and could be important as therapeutic targets for innovative strategies to treat MDS patients.
Materials and methods

Antibodies and reagents
The following antibodies and reagents were purchased from commercial sources. Patients and isolation of mononuclear cells from bone marrow and peripheral blood Bone marrow and peripheral blood samples were obtained from 31 patients with MDS and from healthy donors who had given informed consent in accordance with institutional guidelines. In all 31 subjects who participated in this study, the diagnosis was defined according to the French-American-British (FAB) classification, while the International Prognostic Scoring System (IPSS) was utilized to divide the patients in two categories (low-and high-risk MDS, see Results). For in vitro experiments, BMMCs and PBMCs were isolated by Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden) density-gradient centrifugation. Patients were selected only if multiple samples were available for repeated analysis.
Tissue cell culture
Human Jurkat T-cell leukemia and HL60 myeloid leukemia cells were cultured at 371C with 5% CO 2 in RPMI 1640 medium (Cambrex Bio Science, Verviers, Belgium) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and streptomycin/penicillin at an optimal cell density of 0.3-0.8 Â 10 6 cells/ml.
Immunocytochemistry and flow cytometric analysis
Freshly isolated BMMCs and PBMCs, or frozen samples rapidly thawed on ice, were collected by centrifugation and resuspended in bone marrow cell culture medium (Qbiogene Molecular Cytogenetics, Irvine, CA, USA) at a density of 0.3 Â 10 6 cells/ml. Cells were plated on electrostatically charged glass slides using a Shandon Cytospin (Thermo Electron Corporation, Pittsburgh, PA, USA) at medium acceleration and 800 rpm/min for 4 min. Slides were fixed in 4% formaldehyde (Sigma) in phosphate-buffered saline (PBS, pH 7.4) for 10 min at room temperature, after which cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min. Slides were incubated with primary antibodies diluted in 1% bovine serum albumin (BSA) in PBS overnight at 41C, washed 3 Â 5 min with PBS, and incubated with Cy3-conjugated secondary antibody (1:2000) or FITC-conjugated secondary antibody (1:200) for 30 min at room temperature. Control experiments were performed using the secondary antibodies only. To visualize nuclei, samples were incubated for 1 min with 4 0 ,6-diamidino-2-phenylindole (DAPI). Slides were mounted in ProLong Antifade (Molecular Probes, Eugene, OR, USA) and examined under epifluorescent illumination. Images were taken on a Zeiss Axio Imager.Z1 microscope, with 60x/NA 1.40 optics, coupled to a computer driven Zeiss AxioCAM digital camera (MRm), using Zeiss Axio Vision (4.4) software and constant settings for exposure. For quantification of immunoreactivity, 50-100 cells/slide were counted.
Flow cytometry analysis was performed as recently described by Tazzari et al. 25 Briefly, BMMCs (0.2 Â 10 6 cells/sample) were fixed according to the manufacturer's instructions (Beckman Coulter, Miami, FL, USA) and permeabilized with a saponinbased reagent. To detect intracellular p-Akt protein expression, cells were incubated with an antibody to Ser473 p-Akt for 12 h at 41C, washed with PBS and incubated with an FITCconjugated secondary antibody. Negative controls were performed by incubating cells with FITC-conjugated secondary antibody only. To exclude that positive staining was due to nonspecific binding of antibodies to Fc receptors, 26 cells were preincubated with 5 ml of a mouse blocking anti-human CD16 IgG 27 for 1 h at 371C before performing the intracellular p-Akt staining. All the samples were analyzed by EPICS XL and Cytomics FC 500 flow cytometers (Beckman Coulter) equipped with dedicated software. Histograms were then analyzed with expo software.
Western immunoblotting and phospho-Akt (Ser473 p-Akt) ELISA
Equal number of cells (4 Â 10 6 ) from Jurkat, HL60, and control PBMCs were collected by centrifugation and lysed by adding 200 ml 1 Â SDS sample buffer (62.5 mM Tris-HCl (pH 6.8 at 251C), 2% w/v SDS, 10% glycerol, 50 mM dithiothreitol) and kept on ice. Samples were sonicated 10 s, heated to 951C for 5 min, cooled on ice, and microcentrifuged for 5 min. Equal protein amounts (75 mg) were separated by SDS-PAGE, electrotransferred to nitrocellulose membrane, and nonspecific antibody binding sites were blocked by incubation in blocking buffer (1 Â PBS, 0.1% Tween-20 (PBS/T) with 5% w/v nonfat dry milk) for 1 h at room temperature. After PBS/T wash, membranes were incubated with primary antibodies overnight at 41C in 10 ml PBS/T with 5% BSA, for a polyclonal antibody, or 5% nonfat dry milk, for a monoclonal antibody. After washes with PBS/T, membranes were incubated with HRP-conjugated secondary antibody (1:2000) in PBS/T for 1 h at room temperature, followed by PBS/T washing. Proteins were detected by incubating the membrane with LumiGLO s detection reagent.
The phospho-ELISA kit was used according to the manufacturer's instructions. Equal concentrations of protein extract (200 mg/ml) were analyzed for the expression of Ser473 p-Akt. The intensity of the color reaction, measured in a multi-well plate reader at 450 nm, is directly proportional to the concentration of Ser473 p-Akt in the original sample. Values were expressed as fraction of the amount of Ser473 p-Akt observed in Jurkat cell extract, which was normalized to 1.
Results
Patients characteristics
BMMC and PBMC fractions from 31 patients diagnosed with MDS were examined in this study. Patient demographics and disease characteristics are summarized in Table 1 
Comparison of Ser473 p-Akt levels in Jurkat, HL60, and mononuclear cells from healthy donors
Since we decided to evaluate Ser473 p-Akt in MDS patients by either immunocytochemistry or flow cytometry, a very critical issue concerned the specificity of the antibodies used. To investigate the Ser473 p-Akt antibody specificity and sensitivity, a number of control experiments were performed. To this end, the expression of Ser473 p-Akt was investigated in the Jurkat cell line (human T-cell leukemia), having a constitutive activation of Akt, 29 and in the HL60 cell line (human myeloid leukemia), having none or very low levels of p-Akt. 30 Figure 1a shows the expression of Ser473 p-Akt in Jurkat cells, HL60 cells and normal BMMCs when investigated by immunofluorescence. Jurkat cells expressed high levels of Ser473 p-Akt, while HL60 cells, and normal BMMCs demonstrated very low immunoreactivity towards Ser473 p-Akt antibody, the latter in agreement with previous reports. 31 All cells analyzed (Jurkat, HL60 and control BMMCs and PBMCs) always expressed total Akt (data not shown). Control experiments were also performed excluding the primary antibody to verify that the secondary antibody did not result in unspecific immunostaining (data not presented). The levels of Ser473 p-Akt were also investigated by Western blot analysis (Figure 1b) and ELISA (Figure 1c 
Ser473 p-Akt levels in normal and MDS mononuclear cells
The level of Akt activation was investigated in BMMCs and PBMCs from healthy donors and MDS patients. Owing to the low number of cells purified from some MDS patients, the level of Ser473 p-Akt was investigated by either immunocytochemistry or flow cytometry, where 0.5-1 Â 10 6 cells is sufficient for analysis. Lineage identity of cells was established by immunolabeling with one of the following two myeloid-specific surface markers, CD33 or MPO.
32 Figure 2 shows the expression of Ser473 p-Akt in normal BMMCs (Figure 2a-c) , and is compared to that of BMMCs from two high-risk MDS patients (Figure 2d Table 2 .
Flow cytometry analysis corroborated the results obtained by immunocytochemistry. This is illustrated in Figure 3 Table 2 . Negative controls were also performed by incubating cells with FITC-conjugated 26 BMMCs from a high-risk MDS patient (case 31) were preincubated with anti-CD16 to block Fc receptors 27 prior to p-Akt intracellular staining. However, this treatment did not lower the immunoreactivity towards p-Akt (Figure 3 ). In conclusion, 90% of the high-risk MDS patients (n ¼ 22) analyzed for Ser473 p-Akt expression demonstrated higher levels of p-Akt (from þ þ to þ þ þ þ , see Table 2 ) compared to healthy donors or low-risk MDS patients (n ¼ 9). Finally, BMMCs and PBMCs from both high-and low-risk MDS patients always expressed total Akt (data not shown).
Elevated expression of the PI3K p110d isoform in mononuclear cells from MDS patients
It has been demonstrated that the PI3K p110d isoform is consistently expressed at high levels in AML blasts, and that selective pharmacological inhibition of this isoform suppresses Akt activation and proliferation of AML blasts without affecting the proliferation of normal hematopoietic progenitor cells. 24 We investigated the protein levels of the PI3K p110d subunit in Jurkat cells, normal PBMCs, and MDS BMMCs or PBMCs. Figure 4a shows the expression of the PI3K p110d isoform in Jurkat cells and normal PBMCs, as investigated by Western blot analysis. When analyzed by immunofluorescence, Jurkat cells' and healthy donors' PBMCs displayed a moderately positive staining for PI3K p110d (Figure 4b) . Furthermore, as seen in Figure 4b , PI3K p110d expression in BMMCs from high-risk MDS patients (cases 11 and 23) was consistently higher when compared to healthy donor PBMCs. Generally, low-risk MDS patients (Figure 4b ; cases 8 and 30) expressed lower levels of PI3K p110d than high-risk MDS patients. Data for all 16 patients analyzed are shown in Table 2 . In conclusion, these results suggest that an increased expression of the catalytically active p110d subunit of the PI3K in high-risk MDS patients might result in an increased activity in the PI3K/ Akt signaling pathway with an upregulated Akt phosphorylation as a consequence.
Correlation of PTEN expression and elevated levels of p-AKT
The upregulation of Akt activity appears to be a common event in PTEN-controlled tumorigenesis. 12 Lack of PTEN expression has been reported in AML blasts displaying constitutive Akt activation.
15 Figure 5a shows a Western blot analysis of PTEN expression in Jurkat cells that are PTEN negative, 29 and normal PBMCs, which express high amounts of PTEN. 33 In Figure 5b , immunofluorescence analysis confirmed that Jurkat cells express no PTEN, while healthy donor PBMCs demonstrated high PTEN staining intensity. MDS patients analyzed for PTEN expression showed different levels of expression of PTEN, where all highrisk MDS cases analyzed consistently demonstrated low PTEN expression, while low-risk MDS cases showed variable levels of PTEN. In Figure 5b , PTEN staining in BMMCS from two high-risk 
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Discussion
In this investigation, we demonstrate an increased level of phosphorylation (activation) of Akt in MDS. Constitutive activation of Akt is associated with cell survival, as active Akt can phosphorylate and inactivate a number of proapoptotic downstream targets. To our knowledge, this is the first report that indicates a constitutive activation of Akt in mononuclear cells from high-risk MDS patients. We have examined the levels of Akt phosphorylation, by immunocytochemical and flow cytometry analysis, in PBMCs and BMMCs from high-and low-risk MDS patients, using normal PBMCs or BMMCs as controls for comparison of staining intensity. Furthermore, human T-cell leukemia (Jurkat), with constitutive activation of Akt, was used as a positive control for high Ser473 p-Akt staining. MDS is marked by ineffective bone marrow hemopoiesis, and bone marrow cell populations are heterogeneous. This results in a limited number of cells available for analysis, and impediments a Western blot or ELISA protein expression analysis. However, for immunocytochemical and flow cytometry, less than 10 6 cells per sample is sufficient for analysis.
Successful treatment of MDS has been hindered by the lack of pathophysiological knowledge associated with this disorder. Early stages of MDS display an increased apoptosis, contributing to ineffective hematopoiesis and peripheral cytopenia. Increased levels of tumor necrosis factor (TNF)a, 34 as well as the insulin-like growth factor-binding protein 3 (IGFBP-3), 35 has been observed and could be responsible for augmented TNFamediated apoptosis. Conversely, later stages of MDS present an excessive survival and leukemic evolution of MDS arises through lesions that inhibit apoptotic control mechanisms. 23 Overexpression of the antiapoptotic protein Bcl-2 has been demonstrated immunohistochemically and by flow cytometry in later stages of MDS. 36 Furthermore, it has been shown that cFLIP( L) , a protein that antagonizes Fas-and TRAIL-mediated apoptosis, is also upregulated. 21, 37 This presents the possibility of defining early prognostic factors of susceptibility for malignant transformation of MDS. 38 However, little information is available on the signal transduction pathways which may be involved in the upregulation of these antiapoptotic factors.
Activation and amplification of multiple components of the PI3K/Akt axis is frequently linked with tumor progression. 4 The importance of the PI3K/Akt signaling pathway, in regulation of cell survival and leukemogenesis, is now well established. 1 Several reports shows that activation the PI3K/Akt pathway protects AML blasts from undergoing apoptosis. 15, 17, 18 As to the causes of p-Akt upregulation in MDS, it should be recalled that Ras mutations may result in dysregulation of PI3K. It has been recently showed that N-Ras mutations are frequently associated with progression of MDS to AML. 39 Interestingly, the inhibition Akt activation in MDS patients M Nyåkern et al of Ras protein activation by the farnesyltransferase inhibitor R115777 has an antitumor activity in MDS patients. 40 Furthermore, it was recently shown that Ras upregulation is important for the constitutive activation of NF-kB transcription factor in AML. 41 Constitutive activation of the PI3K/Akt pathway in highrisk MDS patients might be related to increased NF-kB transcription factor activity which has been detected in these patients. 42 It is interesting to note that expression of the antiapoptotic factor Bcl-2 is regulated via the PI3K/Akt/NF-kB signaling pathway in hematopoietic cells, 43 something that is also true for cFLIP (L) . 44 Activation of the PI3K/Akt survival pathway may also be linked to an overexpression of the PI3K p110d catalytic subunit. This was recently shown to be the case in AML, 24 as well as in neutrophils from MDS patients, although the antibody used in that study did not distinguish between different p110 isoforms. 45 In this study, we show that in mononuclear cells from high-risk MDS patients, there is a relationship between Akt activation and PI3K p110d upregulation. Our results demonstrate that BMMCs and PBMCs from all high-risk MDS patients analyzed (n ¼ 7) displayed an overexpression of the PI3K p110d isoform. This might result an increased activation of the PI3K signaling pathway, with an upregulated Akt phosphorylation as a consequence. Interestingly, eight out of nine low-risk MDS patients analyzed demonstrated a lower expression of both p-Akt and the PI3K p110d isoform.
Alternatively, the increased p-Akt levels observed in high-risk MDS patients could be due to the loss of expression of PTEN, which negatively regulates the level of PtdIns(3,4,5)P 3 and thus 
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M Nyåkern et al the activation of Akt. Lack of PTEN expression has been reported in AML blasts displaying constitutive Akt activation, 15 although this was not confirmed in a later investigation. 46 In this study, high-risk MDS patients consistently expressed PTEN, albeit to a much lower extent compared to healthy donors. Low-risk MDS patients demonstrated a more variable expression of PTEN, where about 50% of the low-risk patients had a higher PTEN expression compared to high-risk MDS patients. The decreased expression of PTEN observed in MDS cells could in part explain the increased levels of p-Akt observed in high-risk MDS. However, evidently we cannot rule out that PTEN inactivating mutations could also be present, resulting in an increased activation of the PI3K/Akt axis.
In summary, we have demonstrated for the first time a constitutive activation of Akt in BMMCs and PBMCs from patients diagnosed with high-risk MDS. Conversely, low-risk MDS patients do not demonstrate any activation of the Akt survival pathway. Future investigations should be aimed at defining the importance of the PI3K/Akt pathway for the survival of primary MDS cells and other survival pathways known to be upregulated in AML, that is, the p42/44 MAP kinase network. 47 These experiments could provide evidence that the PI3K/Akt survival network contributes to malignant growth of MDS cells, and inhibition of such an intracellular signaling pathway could be an attractive target to develop innovative therapeutic strategies aimed at preventing evolution of MDS into AML. 
